Roche Holding AG
Roche Holding AG를 보는 글로벌 시선
이 종목 직접 발언을 우선한 글로벌 증권사·투자대가의 공개 원문 · RICHMAP 추천 아님
재무 요약
Finnhub /stock/metric · 연간 기준 · 캐시 6h▸ Finnhub /stock/profile2 · 캐시 24h · 모든 수치 API 원값 (RICHMAP 가공·추정 없음)
관련 뉴스
Finnhub /company-news · 최근 14일 · 캐시 30minSIG vs. CFRUY: Which Stock Should Value Investors Buy Now?
SIG vs. CFRUY: Which Stock Is the Better Value Option?
원문 보기 ↗ YahooOlema Pharmaceuticals Shares Fall 15.1% Following AstraZeneca SERENA-4 Trial Results
Olema Pharmaceuticals (NASDAQ:OLMA) shares fell 15. 1% in pre-market trading to $8.
원문 보기 ↗ YahooAstraZeneca breast cancer drug fails trial but Citi keeps 'buy' rating
AstraZeneca PLC's (LSE:AZN, NASDAQ:AZN) experimental breast cancer drug camizestrant has failed a late-stage trial, though analysts at Citi say the setback does little to dent the company's prospects.…
원문 보기 ↗ YahooBig Pharma Is Pouring Billions Into China’s Biotechs
Big Pharma firms have cut license deals worth tens of billions of dollars for cancer drugs invented in China.
원문 보기 ↗ YahooReported Saturday, Roche's B7-H3-Targeted ADC Tam-Peli Meets Primary Endpoint In Phase III TAISHAN-302 Trial, China's NMPA Accepts New Drug Application For Filing
Tambotatug pelitecan (Tam-Peli) demonstrated statistically significant efficacy over topotecan in a phase III study conducted in China, reducing the risk of death by 54% and disease progression by 71%…
원문 보기 ↗ BenzingaRoche’s collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancer
Tambotatug pelitecan (Tam-Peli) demonstrated statistically significant efficacy over topotecan in a phase III study conducted in China, reducing the risk of death by 54% and disease progression by 71%…
원문 보기 ↗ YahooEXEL Stock Slides After FDA Adds Three Months To Cancer Drug Review — William Blair Sees More Swings In Near Term
The FDA told Exelixis on Thursday that it had extended the review of a new drug application for zanzalintinib plus Roche’s Tecentriq in patients whose colorectal cancer has spread.
원문 보기 ↗ YahooExelixis, An IBD 50 Stock, Pulls A Bearish Move With Surprise Cancer Delay
Exelixis stock dropped out of a buy zone Friday after the FDA delayed the potential approval of its new colon cancer treatment.
원문 보기 ↗ YahooMRK Banks on Growing Pipeline & New Drugs to Offset Keytruda LOE
Merck is expanding its pipeline and newer drug portfolio to offset Keytruda's 2028 LOE and drive long-term growth.
원문 보기 ↗ YahooAMGN, AZN Drug Combo Shows Survival Benefit in Lung Cancer Study
Amgen and AstraZeneca's Imdelltra-Imfinzi combo shows survival benefits in first-line ES-SCLC, potentially broadening both drugs' reach.
원문 보기 ↗ YahooRoche Gets FDA Priority Tag for Enspryng in Rare Autoimmune Disorder
RHHBY's sBLA for Enspryng wins FDA priority tag for myelin oligodendrocyte glycoprotein antibody-associated disease. A decision is due on Jan. 10, 2027.
원문 보기 ↗ YahooRoche’s Genentech Gets FDA Priority Review for Enspryng in MOGAD
The FDA is expected to decide by January 10, 2027, after a Phase III study showed Enspryng reduced the risk of MOGAD relapse by 68% versus placebo. Key Investor TakeawaysGenentech, part of Roche (USOT…
원문 보기 ↗ Yahoo내 성향 트레이더로 도전
주어는 당신의 성향이지 이 종목이 아닙니다. 6시간부터 1년까지 운용기간을 고르면, AI가 기간에 맞는 주기로 가상 매매합니다. 페이지를 닫아도 서버에서 계속 진행됩니다.
트레이더 성향 설정
객관식만 · 주관식 0 · 생성 후 변경 불가
본 페이지는 정보 제공 목적의 종목 정보 색인이며, 투자 권유·자문·중개가 아닙니다. RICHMAP은 증권사·금융투자업자가 아닙니다. 시세·재무·뉴스는 외부 데이터 소스(Finnhub 등)의 정보로 실시간성·정확성을 보증하지 않습니다. 모든 수치는 API 원값으로 RICHMAP의 가공·추정이 없으며, 조회 실패 시 "데이터 없음"으로 명시됩니다. 투자 판단과 그 결과 책임은 본인에게 있으며, 실제 거래는 정식 인가 증권사를 통해 본인 판단하에 진행하시기 바랍니다.